BME (Blackrock Health Sciences Trust)
Insider Trading Activity
Every open-market purchase and sale reported by BME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | H Erin Xie | — | MIXED | — | — |
| 2026-02-03 | Xiang Liu | — | MIXED | — | — |
| 2025-02-04 | Kyle McClements | — | MIXED | — | — |
| 2025-02-04 | Christopher Accettella | — | MIXED | — | — |
| 2025-02-04 | Xiang Liu | — | MIXED | — | — |
| 2025-02-04 | H Erin Xie | — | MIXED | — | — |
| 2024-04-30 | Kyle McClements | — | — | — | — |
| 2024-02-02 | Kyle McClements | — | MIXED | — | — |
| 2024-02-02 | Xiang Liu | — | MIXED | — | — |
| 2024-02-02 | Christopher Accettella | — | MIXED | — | — |
| 2024-02-02 | H Erin Xie | — | MIXED | — | — |
| 2023-02-02 | Xiang Liu | — | MIXED | — | — |
| 2023-02-02 | Kyle McClements | — | MIXED | — | — |
| 2023-02-02 | Christopher Accettella | — | MIXED | — | — |
| 2023-02-02 | Jeffrey Gene Lee | — | MIXED | — | — |
| 2023-02-02 | H Erin Xie | — | MIXED | — | — |
| 2022-02-03 | Christopher Accettella | — | MIXED | — | — |
| 2022-02-03 | Kyle McClements | — | MIXED | — | — |
| 2022-02-02 | Jeffrey Gene Lee | — | MIXED | — | — |
| 2022-02-02 | Xiang Liu | — | A | — | — |
| 2022-02-02 | H Erin Xie | — | MIXED | — | — |
| 2021-02-02 | Jeffrey Gene Lee | — | A | — | — |
| 2021-02-02 | Christopher Accettella | — | MIXED | — | — |
| 2021-02-02 | Kyle McClements | — | MIXED | — | — |
| 2021-02-02 | H Erin Xie | — | MIXED | — | — |
| 2020-02-04 | Christopher Accettella | — | MIXED | — | — |
| 2020-02-04 | H Erin Xie | — | MIXED | — | — |
| 2020-02-04 | Kyle McClements | — | MIXED | — | — |
| 2019-07-02 | Cynthia Egan | Director | Buy | — | — |
| 2019-02-04 | Christopher Accettella | — | MIXED | — | — |
| 2019-02-04 | Kyle McClements | — | MIXED | — | — |
| 2019-02-04 | H Erin Xie | — | MIXED | — | — |
| 2018-10-17 | Catherine A. Lynch | Director | A | — | — |
| 2018-10-17 | W CARL KESTER | Director | A | — | — |
| 2018-10-17 | ROBERT GLENN HUBBARD | Director | A | — | — |
| 2018-10-17 | RICHARD CAVANAGH | Director | A | — | — |
| 2018-10-17 | Michael J Castellano | Director | A | — | — |
| 2018-10-17 | KAREN P ROBARDS | Director | A | — | — |
| 2018-07-17 | Michael J Castellano | Director | A | — | — |
| 2018-07-17 | W CARL KESTER | Director | A | — | — |
| 2018-07-17 | RICHARD CAVANAGH | Director | A | — | — |
| 2018-07-17 | KAREN P ROBARDS | Director | A | — | — |
| 2018-07-17 | Catherine A. Lynch | Director | A | — | — |
| 2018-07-17 | ROBERT GLENN HUBBARD | Director | A | — | — |
| 2018-04-17 | Michael J Castellano | Director | A | — | — |
| 2018-04-17 | W CARL KESTER | Director | A | — | — |
| 2018-04-17 | RICHARD CAVANAGH | Director | A | — | — |
| 2018-04-17 | KAREN P ROBARDS | Director | A | — | — |
| 2018-04-17 | Catherine A. Lynch | Director | A | — | — |
| 2018-04-17 | ROBERT GLENN HUBBARD | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 11,449 | — |
| — | Director | 3,737 | — |
| — | Director | 1,100 | — |
| — | — | 1,022 | — |
| — | Director | 875 | — |
| — | — | 593 | — |
| — | Director | 500 | — |
| — | Director | 400 | — |
| — | — | 204 | — |
| — | Director | 100 | — |
| — | Director | 100 | — |
| — | Director | 100 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BME quote page; the site-wide leaderboard is on the insider transactions hub.